Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE vs HYDROCODONE BITARTRATE AND ACETAMINOPHEN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Hydrocodone is a full mu-opioid receptor agonist, exerting analgesic and antitussive effects by binding to opioid receptors in the CNS and cough center. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
Relief of cough and symptoms of upper respiratory allergies or common cold, including nasal congestion, rhinorrhea, sneezing, and sinusitis
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate.
1 tablet (hydrocodone 5 mg/chlorpheniramine 4 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
Oral: 1-2 tablets (5-10 mg hydrocodone/325-650 mg acetaminophen) every 4-6 hours as needed for pain; maximum daily doses: hydrocodone 40 mg, acetaminophen 3000 mg.
Hydrocodone: 3.8-8.5 hours (mean 5.3 hours); context: immediate-release, dosing intervals typically 4-6 hours. Chlorpheniramine: terminal half-life 12-43 hours (mean 21 hours); context: longer half-life supports twice-daily dosing, but effects may not correlate linearly.
Hydrocodone: 3.8-7.4 hours (terminal), prolonged in hepatic impairment. Acetaminophen: 1.5-2.5 hours (terminal).
GFR 30-50: administer every 6 hours; GFR <30: avoid use due to accumulation of hydrocodone metabolites and risk of CNS depression.
e GFR 30-89 m L/min: No adjustment. e GFR <30 m L/min: Avoid use or reduce dose and frequency. Hemodialysis: Not recommended.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; CYTOCHROME P450 3A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; RISK OF MEDICATION ERRORS; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS OF CONCOMITANT USE WITH MAOIs.
First trimester: Opioid exposure associated with neural tube defects, congenital heart defects, and gastroschisis in some studies; antihistamine not associated with major malformations. Second/third trimester: Chronic use may lead to fetal opioid dependence, placental insufficiency, preterm labor, and intrauterine growth restriction. At delivery: Neonatal opioid withdrawal syndrome (NOWS) is expected if maternal use near term.
First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: Chronic use may cause fetal opioid dependence, neonatal withdrawal syndrome, and reduced fetal growth. Acetaminophen component: no known teratogenic risk at therapeutic doses.
Hydrocodone/chlorpheniramine is a fixed-dose combination antitussive/antihistamine. The hydrocodone component has opioid agonist activity; monitor for respiratory depression, especially in COPD or sleep apnea. Chlorpheniramine is a first-generation antihistamine with anticholinergic effects; avoid in narrow-angle glaucoma, urinary retention, and prostatic hypertrophy. Note that the combination product is Schedule II due to hydrocodone content. Use with caution in patients on MAOIs or within 14 days of discontinuation due to risk of hypertensive crisis.
Hydrocodone/acetaminophen carries a boxed warning for addiction, abuse, and misuse; respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; and hepatotoxicity (acetaminophen). Avoid in patients with severe respiratory depression, acute or severe bronchial asthma, GI obstruction, or known acetaminophen hypersensitivity. Maximum acetaminophen dose from all sources should not exceed 4 g/day (3 g/day in at-risk patients). Use with caution in elderly, cachectic, or debilitated patients due to increased risk of respiratory depression. CYP3A4 inducers (e.g., rifampin) may reduce hydrocodone efficacy; CYP3A4 inhibitors (e.g., ketoconazole) may increase toxicity. Do not combine with other CNS depressants without dose adjustment. Monitor for signs of opioid-induced constipation; prescribe a bowel regimen. Prescribe immediate-release formulations only for acute pain (generally ≤3 days). Avoid combining with MAOIs or within 14 days of MAOI use.
No interactions on record
No interactions on record
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE and HYDROCODONE BITARTRATE AND ACETAMINOPHEN are distinct pharmacological agents. HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE belongs to the Opioid Agonist class and is primarily used for Relief of cough and symptoms of upper respiratory allergies or common cold, including nasal congestion, rhinorrhea, sneezing, and sinusitis. HYDROCODONE BITARTRATE AND ACETAMINOPHEN belongs to the Opioid Agonist class and is primarily used for Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate.. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE carries a safety status of Category D/X, whereas HYDROCODONE BITARTRATE AND ACETAMINOPHEN safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Hydrocodone is primarily metabolized by CYP3A4 and CYP2D6 to hydromorphone (active) and norhydrocodone. Chlorpheniramine is metabolized by CYP2D6 and other pathways.
Hydrocodone: primarily CYP3A4 and CYP2D6 to hydromorphone (active). Acetaminophen: primarily glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation to NAPQI (toxic).
Hydrocodone: primarily renal excretion as unchanged drug and conjugated metabolites (approx. 26% unchanged); minor biliary/fecal elimination. Chlorpheniramine: renal excretion of metabolites and unchanged drug (approx. 30% unchanged), with some fecal elimination.
Renal excretion of metabolites (hydrocodone: ~60% as conjugates, <12% unchanged; acetaminophen: ~85-90% as glucuronide and sulfate conjugates, <5% unchanged). Biliary/fecal elimination of minor metabolites.
Hydrocodone: 19-45% bound to plasma proteins (mainly albumin). Chlorpheniramine: approximately 70% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein).
Hydrocodone: ~20-50% bound to albumin and other proteins. Acetaminophen: 10-25% bound to albumin.
Hydrocodone: Vd 4.7 L/kg (total body water distribution, moderate tissue binding). Chlorpheniramine: Vd 3-7 L/kg (extensive tissue distribution, high tissue binding).
Hydrocodone: 3.3-4.7 L/kg (extensive tissue distribution). Acetaminophen: 0.75-1.0 L/kg (primarily total body water).
Oral: Hydrocodone bioavailability approximately 50-70% (first-pass metabolism). Chlorpheniramine bioavailability 25-50% (significant first-pass metabolism).
Oral: Hydrocodone ~70-80% (first-pass metabolism). Acetaminophen ~60-90% (product dependent).
Child-Pugh A: no adjustment; Child-Pugh B or C: avoid use or reduce dose by 50% and monitor for excessive sedation.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce total daily dose by 50% or extend dosing interval. Child-Pugh C: Avoid use.
Not recommended for children under 18 years of age due to risk of respiratory depression from hydrocodone.
Not recommended for children <18 years due to safety concerns. For postoperative tonsillectomy/adenoidectomy: contraindicated.
Initiate with half the usual adult dose, extend dosing interval to every 6 hours, and monitor closely for sedation and respiratory depression.
Initiate at lowest effective dose (e.g., 2.5 mg hydrocodone/325 mg acetaminophen) and titrate slowly; monitor for CNS depression and constipation. Avoid in renal impairment.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen overdose.
Respiratory depression, drug dependence, abuse potential, risks with CNS depressants, elderly/debilitated patients, hepatic impairment, renal impairment, severe hypotension, head injury, seizures, use in pregnancy, use in breastfeeding, adrenal insufficiency, anaphylaxis, withdrawal, and driving impairment.
Significant respiratory depression, acute or severe bronchial asthma, GI obstruction (including paralytic ileus), hypersensitivity to hydrocodone or acetaminophen, severe hepatic impairment, and known or suspected gastrointestinal obstruction.
Avoid alcohol and any foods or drinks containing alcohol (e.g., beer, wine, liquor, some mouthwashes, and desserts with alcohol) due to additive CNS depression. Grapefruit juice may alter hydrocodone metabolism; consider avoiding. No specific restrictions for chlorpheniramine.
Avoid alcohol consumption due to increased risk of hepatotoxicity and additive CNS depression. Grapefruit juice may inhibit CYP3A4 and potentially increase hydrocodone levels; consider avoiding or limiting intake. No significant food restrictions otherwise; may take with or without food. Maintain adequate hydration to prevent constipation.
Hydrocodone is excreted into breast milk in low concentrations (M/P ratio approximately 0.2-0.5), but can accumulate in infants of ultrarapid CYP2D6 metabolizers. Chlorpheniramine is also excreted but levels are low. Use cautiously; monitor infant for sedation, respiratory depression, or poor feeding. The American Academy of Pediatrics considers hydrocodone compatible with breastfeeding with caution; chlorpheniramine is generally considered safe.
Hydrocodone is excreted into human breast milk, with an M/P ratio approximately 2.5. Postpartum use may lead to infant sedation and respiratory depression, especially in CYP2D6 ultra-rapid metabolizers. Acetaminophen is excreted in low levels. Use is generally avoided due to risks; if used, monitor infant for drowsiness and feeding difficulties.
Pregnancy may alter pharmacokinetics: increased renal clearance, expanded plasma volume, and changes in hepatic metabolism. The need for dose adjustment is variable; but due to higher clearance in pregnancy, some patients may require increased doses for adequate pain control. However, careful titration to avoid maternal or fetal toxicity is necessary. There is no standardized dose adjustment; individualize based on response and tolerance.
No dosing adjustment recommended specifically for pregnancy, but pharmacokinetic changes (increased clearance, volume of distribution) may result in lower serum concentrations; however, due to fetal risks, use the lowest effective dose for the shortest duration. Avoid use in third trimester unless necessary; monitor for neonatal withdrawal.
This medication contains hydrocodone, an opioid, which can lead to addiction, abuse, and misuse.,Do not take with alcohol or other CNS depressants (e.g., sedatives, tranquilizers) as it may cause severe drowsiness or breathing problems.,May cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid use of other antihistamines or cold medicines without consulting your healthcare provider.,Take exactly as prescribed; do not increase dose or frequency.,Constipation is common; increase fluid and fiber intake. If severe, contact your doctor.,Keep out of reach of children; accidental ingestion can be fatal.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or dissolve extended-release tablets; swallow whole.,Avoid alcohol and any products containing acetaminophen (e.g., Tylenol, cold medicines) to prevent liver damage.,Do not drive or operate heavy machinery until you know how this medication affects you.,Store in a secure place away from children and pets; dispose of unused medication via a drug take-back program.,Contact your doctor immediately if you experience shallow breathing, difficulty waking, confusion, or signs of allergic reaction.,Do not stop abruptly; withdrawal symptoms include anxiety, sweating, diarrhea, and muscle aches.,Inform all healthcare providers that you are taking this medication.,Use exactly as directed; misuse can lead to addiction, overdose, or death.